Keep Updated

Washington Summary February 2018

Health Research and Other Spending Programs On Feb. 9, Congress approved the Bipartisan Budget Act of 2018 that kept government departments and agencies (such as NIH) open until March 23. The short-term funding bill is part of a larger budget […]

PKD Foundation |

Washington Summary January 2018

Second Session of Congress Begins Congress has returned for what could be a busy 2018. The agenda includes the children’s health program (CHIP) and a number of non-health-related national issues: raising the debt ceiling so the US can pay its […]

PKD Foundation |

Washington Summary December 2017

Tax Reform and Health Care The details of the final tax bill (HR 1) were released on Dec. 15. Here are the provisions impacting health-related issues. Deduction of medical expenses: The final bill states that for two years (2017 and […]

PKD Foundation |

Washington Summary November 2017

Health Care Congress continues to discuss ways to stabilize the ACA individual insurance market. More than 200 groups have endorsed the proposal drafted by Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA). Other Senators and Representatives have their own proposals […]

PKD Foundation |

Washington Summary October 2017

Health Care On Sept. 26, Senate Majority Leader Mitch McConnell (R-KY) indicated that the Senate would not vote on the most recent attempt to amend the Affordable Care Act (ACA).  Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA) may seek […]

PKD Foundation |

Tolvaptan and lixivaptan: what’s the difference?

In response to the news about lixivaptan’s orphan drug designation, there have been questions from the PKD community about the difference between the investigational drug and another potential ADPKD treatment, tolvaptan. Tolvaptan and lixivaptan are vasopressin V2 receptor antagonists, meaning […]

PKD Foundation |

Lixivaptan granted orphan drug status for ADPKD

An investigational drug being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD) has received orphan drug designation by the U.S. Food and Drug Administration (FDA). Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which may delay […]

PKD Foundation |

Washington Summary September 2017

Big Budget Picture Congress has a busy fall schedule. The major proposals include approving spending for FY18, ensuring that federal debts are paid, dealing with immigration, and reducing certain taxes. Congress also may try to change or improve certain parts […]

PKD Foundation |

Research Update from Peter Harris, Ph.D., Mayo Clinic

Advances in Gene Editing; Implications for PKD Presently, treatment options in ADPKD focus on addressing changes in cellular pathways, such as increased proliferation or altered secretion that are thought to promote cystic expansion. However, theoretically in a simple genetic disease, […]

PKD Foundation |

Washington Summary August 2017

Health Care Reform In the early morning of July 28, the Senate failed to approve any changes to the Affordable Care Act (ACA or Obamacare). Majority Leader Mitch McConnell (R-KY) pulled the ACA repeal/replace bill from the legislative calendar for […]

PKD Foundation |